|
|
|
| Analysis of the funding situation of the National Cancer Institute and its implications for the distribution of cancer prevention and control technology in China |
| DU Jun1 CHEN Wanqing2 ZHAO Heling1 XIE Yu1 GAO Wenhong1 LIU Zhihua3 |
1.Office of Academic Research, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100021, China;
2.Office for Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
3.State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
|
|
|
Abstract Objective To analyze the scientific research layout of the National Cancer Institute (NCI) in the United States in the past 20 years, and to provide reference for the policy formulation of cancer prevention and control strategy and scientific research investment layout in China. Methods The funding data for fiscal years 1998-2018 were retrieved from the national cancer institute database to analyze the overall situation, funding structure, key support areas, institutions, and the relationship with the cancer burden. Results During the 1998-2018 fiscal year, NCI′s overall funding and research grants had progressively increased. In the structure of funding, research grants had been accounted for absolute proportion; at the meantime, stable support for institutions and non-competitive project funding were focused. The key supporting area had matched the actual demand in cancer prevention and control of America. Conclusion Scientific research plays an important role in supporting the prevention and control of cancer in the United States, and the relevant layout experience of the national cancer institute can be used for reference in formulating strategies to strengthen the scientific and technological support for cancer prevention and control in China.
|
|
|
|
|
|
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Global Burden of Disease Cancer C，Fitzmaurice C，Akin-yemiju TF，et al. Global，Regional，and National Cancer Incidence，Mortality，Years of Life Lost，Years Lived With Disability，and Disability-Adjusted Life-Years for 29 Cancer Groups，1990 to 2016：A Systematic Analysis for the Global Burden of Disease Study [J]. JAMA Oncol，2018，4（11）：1553-1568.
[3] 陈万青，曹毛毛.加强癌症早诊早治，实施健康中国战略[J].中国肿瘤，2019，28（9）：643-645.
[4] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[5] 雷南，刁一凡，白慧君，等.美国癌症谱变化及其防治策略研究[J].中华预防医学杂志，2019，53（7）：737-743.
[6] 周艳，姜军.美国国家癌症研究所介绍[J].中华乳腺病杂志：电子版，2007；1（6）：封2.
[7] Yu S，Yang CS，Li J，et al. Cancer Prevention Research in China [J]. Cancer Prev Res （Phila）2015，8（8）：662-674.
[8] 健康中国行动-癌症防治实施方案（2019-2022年）[J].中国肿瘤，2019，28（11）：803-806.
[9] 石欣，龚侃，王少为，等.美国国家癌症研究所（National Cancer Institute）—美国癌症研究和资助的主要机构[J].生命科学，2004，16（4）：254-258，225.
[10] 冯虎.美国“癌症登月计划”的研究与启示[J].全球科技经济瞭望，2018，33（1）.
[11] 陈宁.美国国立卫生研究院系列调研（一）-基本概况[J].全球科技经济瞭望，2008，23（3）：39-47.
[12] 金楠，王云屏，杨洪伟，等.我国卫生研发的政府投入核算与分析[J].中国卫生经济，2016，35（2）：38-41.
[13] 黄河浪，林菲，曾妮，等.论我国癌症流行现况与综合防控的国家战略[J].中国卫生事业管理，2016，33（11）：875-877.
[14] 吕群燕，张农.NIH支持青年科研人员成长的资助体系及其启示[J].中国基础科学，2008，10（2）：45-50.
[15] 朱迎春.创新型国家基础研究经费配置模式及其启示[J].中国科技论坛，2018（2）：15-22.
[16] 刘太刚，刘开君.论我国竞争性科研项目经费配置模式的困境及优化路径-兼论竞争性和非竞争性科研经费协调投入机制[J].天津行政学院学报，2017，19（5）：3-10.
[17] 国务院副总理孙春兰考察国家癌症中心：加快推进癌症等重大疾病防治攻关[J].抗癌之窗，2018（2）：1.
[18] 辛红霞，邵倩倩，何慧娟，等.我国临床医学研究中心现状分析[J].中国医院管理，2019，39（8）：32-35.
[19] 田倩飞，张志强，任晓亚，等.科技强国基础研究投入-产出-政策分析及其启示[J].中国科学院院刊，2019，34 （12）：1406-1420.
[20] 杜君，郑荣寿，庄建辉，等.我国食管癌疾病负担与国家自然科学基金基础研究资助情况的相关性分析[J].中国肿瘤，2019，28（4）：246-251.
[21] 魏文强，赫捷.大数据信息化背景下我国肿瘤登记工作的思考[J].中华肿瘤杂志，2019，41（1）：15-18. |
|
|
|
